1[1]Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2 ( 1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995 Jul, 274( 1 ) :329 ～ 336
2[2]Fleishhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural transm Suppl, 2003, 105 ～ 117
3[3]Oshiro Y, Sato S, Kurahashi N, et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[ 4-( 4-phenyl-1-piperazinyl ) butoxy ]-3, 4-dthydro-2 (1H)-quinolinone derivatives. J Med Chem, 1998 Feb, 41 : 658 ～667
4[4]Matsubayashi H, Amano T, Sasa M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacolgy (Berl), 1999 Sep, 146(2) : 139 ～ 143
5[5]Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropschopharmacolgy, 1999 Jun, 20(6) : 612～627
6[6]Inoue A, Seto M, Sugita S, et al. differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat ptiuitary. Brain Res Mol Brain Res, 1998 apr, 55 : 285 ～292
7[7]Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.Neuropsychopharmacology, 2003 May
8[8]Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT ( 1 A) receptor. Eur J Pharmacol, 2002 Apr 26,441(3) : 137 ～140
9[9]Goodnick P J, Jerry JM. aripiprazole: profile on efficacy and safety.Expert Opin Pharmacother, 2002 Dec, 3(12) : 1773 ～ 1781
10[10]Stahl SM. dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J Clin Psychiatry, 2001 Nov, 62 (11 ) : 841 ～ 842
